Investors Purchase High Volume of Centessa Pharmaceuticals Call Options (NASDAQ:CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw some unusual options trading on Tuesday. Stock traders acquired 2,994 call options on the company. This is an increase of approximately 472% compared to the average volume of 523 call options.

Centessa Pharmaceuticals Trading Up 0.4%

Shares of Centessa Pharmaceuticals stock opened at $39.86 on Thursday. The business has a fifty day simple moving average of $26.62 and a 200-day simple moving average of $25.35. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $40.26. The firm has a market cap of $5.82 billion, a price-to-earnings ratio of -21.78 and a beta of 1.25. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, equities analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the transaction, the insider directly owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This represents a 52.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 349,073 shares of company stock worth $9,429,412. Company insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC grew its position in Centessa Pharmaceuticals by 34.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after buying an additional 3,747,475 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Centessa Pharmaceuticals by 12.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after buying an additional 1,246,741 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Centessa Pharmaceuticals by 24.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock valued at $134,480,000 after acquiring an additional 1,045,750 shares during the last quarter. Siren L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 24.8% during the 4th quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after acquiring an additional 800,000 shares in the last quarter. Finally, Commodore Capital LP boosted its stake in shares of Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after acquiring an additional 930,711 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Key Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to acquire Centessa in a deal worth up to $7.8 billion (initial $38.00/share cash plus contingent value rights), which creates a takeover premium and is the primary driver of the stock’s upward move. Eli Lilly to buy Centessa Pharma
• Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40.00, a small upward revision that supports the view the deal price is appropriate. Leerink raises price target
• Neutral Sentiment: Unusual options activity: earlier spikes in call buying and, more recently, a large surge in put purchases (10,659 puts) signal mixed positioning—some traders betting on deal completion/arb, others hedging or speculating on downside. (No single article link)
• Negative Sentiment: Multiple brokerages downgraded CNTA (Needham, Wolfe Research, Stephens), citing valuation or deal-related uncertainty — analyst downgrades can weigh on momentum despite the takeover premium. Needham downgrades
• Negative Sentiment: Several law firms and shareholder groups have announced investigations into whether the sale process and price are fair (Monteverde, Kahn Swick & Foti, Ademi, Halper Sadeh). Potential litigation or challenges to the transaction could delay closing or pressure the spread between market price and deal consideration. Shareholder investigation announced
• Negative Sentiment: Recent quarterly results missed EPS estimates (reported ($0.48) vs. consensus ($0.38)), underscoring ongoing clinical and execution risks outside the transaction context. Centessa earnings miss

Analyst Ratings Changes

CNTA has been the topic of a number of research analyst reports. Leerink Partners reissued a “market perform” rating and set a $40.00 price target (up from $36.00) on shares of Centessa Pharmaceuticals in a report on Wednesday. Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Finally, Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.